{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:45Z","timestamp":1787113665739,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836002002"],"award-info":[{"award-number":["836002002"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116889","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:26:53Z","timestamp":1782019613000},"page":"116889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9731-929X","authenticated-orcid":false,"given":"Cato","family":"Boreel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"de Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-4873","authenticated-orcid":false,"given":"Olivier","family":"van Not","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-4285","authenticated-orcid":false,"given":"Manja","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Been","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6381-1500","authenticated-orcid":false,"given":"Maureen","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-0692","authenticated-orcid":false,"given":"Franchette","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9624-9189","authenticated-orcid":false,"given":"Marye","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Bonenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-6002","authenticated-orcid":false,"given":"Dirk","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hilde Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djura","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7284-9818","authenticated-orcid":false,"given":"Bart","family":"Rikhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion Stevense-den","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-1907","authenticated-orcid":false,"given":"Astrid","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke","family":"Simkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-0662","authenticated-orcid":false,"given":"Michel","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fons","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116889_bib1","year":"2018"},{"key":"10.1016\/j.ejca.2026.116889_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10434-999-0315-x","article-title":"Are locoregional cutaneous metastases in melanoma predictable?","volume":"6","author":"Borgstein","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116889_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.02.007","article-title":"Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature","volume":"45","author":"Sloot","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116889_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17512433.2019.1689121","article-title":"Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma","volume":"12","author":"Read","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejca.2026.116889_bib5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116889_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.soc.2024.11.004","article-title":"Management of in-transit disease: regional therapies, intralesional therapies, and systemic therapy","volume":"34","author":"O\u2019Connor","year":"2025","journal-title":"Surg Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2026.116889_bib7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"10.1016\/j.ejca.2026.116889_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35636","article-title":"A comparison of isolated limb infusion\/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases","volume":"131","author":"DePalo","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116889_bib9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1245\/ASO.2006.07.020","article-title":"Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma","volume":"13","author":"Kretschmer","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116889_bib10","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3390\/cancers16173065","article-title":"Therapeutic treatment options for in-transit metastases from melanoma","volume":"16","author":"Russano","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116889_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000440","article-title":"Efficacy of immune checkpoint inhibitors for in-transit melanoma","volume":"8","author":"Nan Tie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116889_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u22c6","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116889_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116889_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/SLA.0000000000003665","article-title":"The dutch institute for clinical auditing","volume":"271","author":"Beck","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116889_bib15","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.ejca.2026.116889_bib16","author":"Cancer Institute","year":"2017","journal-title":"Common Terminol Criteria Advers Events (CTCAE) Common Terminol Criteria Advers Events (CTCAE) v5 0"},{"key":"10.1016\/j.ejca.2026.116889_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2026.116889_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116889_bib19","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116889_bib20","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: Pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116889_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116889_bib22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116889_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116889_bib24","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00262-020-02839-7","article-title":"T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model","volume":"70","author":"Stahlie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2026.116889_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116889_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-3-S2-P181","article-title":"A Phase I\/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)","volume":"3","author":"Long","year":"2015","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:16:01Z","timestamp":1787112961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"alternative-id":["S0959804926006702"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116889","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116889"}}